In a recent analysis of 87 NTRK fusion-positive cancers, specificity of pan-TRK IHC was 100% for tumors of the colon, lung, thyroid, pancreas, and appendix, as well as in patients with melanoma. This evidence concerns the gene NTRK1 and cancer.